SYDNEY, April 15 (Reuters) - Shares of China's Duality Biotherapeutics 9606.HK were set to rise 91.3% in their Hong Kong debut on Tuesday after the company raised $213 million in an initial public offering launched as financial markets reacted savagely to the U.S tariffs package.
(Reporting by Scott Murdoch in Sydney and Donny Kwok in Hong Kong; Editing by Tom Hogue)
((Scott.Murdoch@thomsonreuters.com;))